Home/Pipeline/Somatic Expansion Inhibitor Program

Somatic Expansion Inhibitor Program

Huntington's Disease

PreclinicalActive

Key Facts

Indication

Huntington's Disease

Phase

Preclinical

Status

Active

Company

LoQus23 Therapeutics

About LoQus23 Therapeutics

LoQus23 Therapeutics is a private, preclinical-stage biotech targeting a novel mechanism in repeat expansion disorders like Huntington's disease. The company, founded by experienced industry veterans, is developing small molecules designed to inhibit somatic expansion of DNA repeats, aiming to halt disease progression at its source. Backed by the Dementia Discovery Fund and led by a team with deep neuroscience and drug discovery expertise, LoQus23 is positioned to address a high-unmet medical need with a potentially disease-modifying approach.

View full company profile

Therapeutic Areas

Neurology Rare Diseases

Other Huntington's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
Huntington's Disease Program	Rumi Scientific	Pre-clinical	Active
SOM3355	SOM Biotech	Phase 3	Active
LETI-101	ElevateBio	Preclinical	Active
Preclinical Program	Excision BioTherapeutics	Preclinical	Active
NA-841	Biomed	Phase 2A	Active
T3D-959 (Future)	T3D Therapeutics	Pre-clinical / Research	Active
HD mAb Therapy	HD Immune	Pre-clinical	Active
TT-P34	Teitur Trophics	Pre-clinical	Active
INT41	Vybion	Pre-clinical	Active
Huntington's Program	reMYND	Pre-clinical	Active
Pridopidine	Prilenia Therapeutics	Phase 3	Active